EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Efficacy of IDOR‐1117‐2520, a novel, orally available CCR6 antagonist in preclinical models of skin dermatitis

Paulina Kulig, Pijus Brazauskas, Madeleine Suffiotti, Emilie Raoult, Ulrike Babilonski, Bérengère Renault, Ursula Grieder, Enrico Vezzali, Peter Blattmann, Marianne M Martinic, Mark J Murphy iD

British Journal of Pharmacology · 2025

DOI: 10.1111/bph.70025 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Pharmacology, 2025. Verfasst von Paulina Kulig und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Translational and Pharmacological Science, Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland. Hauptthemen laut MEDLINE: Receptors, CCR6, Psoriasis, Dermatitis. Die Arbeit nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Purpose The chemokine receptor CCR6 guides pathogenic T17 cells, implicated in autoimmune diseases including psoriasis, to sites of inflammation via the chemokine CCL20. Therefor, pharmacological inhibition of CCR6 + immune cell migration provides a novel therapeutic approach. Translatability of such an intervention has not yet been assessed in detail. We evaluated the translatability of the Aldara® mouse model induced skin inflammation to psoriasis, with particular focus on immune cell trafficking and assessed the efficacy of IDOR‐1117‐2520, a highly selective, potent and orally available CCR6 small inhibitor. Experimental Approach Effects of IDOR‐1117‐2520 were investigated in the Aldara® and IL23 mouse models of skin inflammation using flow cytometry, RNA sequencing and transcriptome‐based cell type deconvolution approaches to characterise immune cell migration patterns. These results were compared to human psoriasis transcriptomics data. Key Results IDOR‐1117‐2520 dose dependently reduced infiltration of CCR6 + immune cells into inflamed skin, and was equally efficacious as IL‐17 and IL‐23 inhibition in models of skin inflammation. Pathway analysis showed molecular similarities in the immune response between human psoriasis and the Aldara® mouse model. IL‐17/IL‐23 pathway genes were expressed in both human psoriasis and the mouse model. CCR6 inhibition modulated multiple pathways associated with inflammation beyond the proximal IL‐17/IL‐23 pathway. A chemokine–chemokine receptor interaction map implicated CCL20‐CCR6 as the dominant axis in recruiting pathogenic T17 cells in both the model and in human psoriasis. Conclusion and Implications IDOR‐1117‐2520 could provide a promising novel targeted approach to treating psoriasis and, potentially, other autoimmune diseases involving the CCR6/CCL20 axis and the IL‐17/IL‐23 pathway. IDOR‐1117‐2520 is currently being evaluated in a clinical phase 1 trial (ISRCTN28892128).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, CCR6PsoriasisDermatitisAnimalsDisease Models, AnimalMiceHumansAdministration, OralFemaleMice, Inbred C57BLMaleChemokine CCL20Skin

Stichwörter der Autor:innen

Aldara® modelCCL20CCR6 antagonistCCR6 inhibitionIDOR‐1117‐2520IL‐17IL‐23T17autoimmune diseasechemokine receptorinflammationinhibition of migrationpsoriasis

Substanzen

Receptors, CCR6CCR6 protein, mouseChemokine CCL20

Autor:innen und Institutionen

  • Department of Translational and Pharmacological Science, Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland.

ORCID-Profile: Mark J Murphy

Zitieren

APA

Kulig, P., Brazauskas, P., Suffiotti, M., Raoult, E., Babilonski, U., Renault, B., Grieder, U., Vezzali, E., Blattmann, P., Martinic, M. M., & Murphy, M. J. (2025). Efficacy of IDOR‐1117‐2520, a novel, orally available CCR6 antagonist in preclinical models of skin dermatitis. British Journal of Pharmacology. https://doi.org/10.1111/bph.70025

Vancouver

Kulig P, Brazauskas P, Suffiotti M, Raoult E, Babilonski U, Renault B, et al. Efficacy of IDOR‐1117‐2520, a novel, orally available CCR6 antagonist in preclinical models of skin dermatitis. British Journal of Pharmacology. 2025. doi:10.1111/bph.70025

BibTeX
@article{Kulig2025,
  author = {Kulig, Paulina and Brazauskas, Pijus and Suffiotti, Madeleine and Raoult, Emilie and Babilonski, Ulrike and Renault, Bérengère and Grieder, Ursula and Vezzali, Enrico and Blattmann, Peter and Martinic, Marianne M and Murphy, Mark J},
  title = {Efficacy of IDOR‐1117‐2520, a novel, orally available CCR6 antagonist in preclinical models of skin dermatitis},
  journal = {British Journal of Pharmacology},
  year = {2025},
  doi = {10.1111/bph.70025}
}
Kostenlos starten →